InflaRx NV (FRA:IF0)
€ 1.35 0 (0%) Market Cap: 85.25 Mil Enterprise Value: 2.44 Mil PE Ratio: 0 PB Ratio: 0.89 GF Score: 32/100

Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call Transcript

Oct 27, 2021 / 12:30PM GMT
Release Date Price: €2.49 (+3.15%)
Jordan Zwick
InflaRx N.V. - Chief Strategy Officer

Hello. Thank you for joining us to discuss the top-line results from the third cohort of the Phase IIa open-label study evaluating vilobelimab in patients with pyoderma gangrenosum. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website following the call.

Before we begin, I'd like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These beliefs are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional details.

With me on the call presenting the data is Professor Niels Riedemann, our CEO and Founder; along with Dr. Hoda Tawfik, our Senior Program Director of Dermatology; our Chief Clinical Development Officer, Dr. Korinna Pilz; and our CFO, Dr. Thomas Taapken, will join the Q&A section at the end of the call. Now I'll turn the call over to Niels.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot